Versi Group, LLC
Records under this name other than patents Versi Group, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,029,496 | Method and device for delivering drug to the trigone of the bladder Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,973,815 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,779,581 | Opioid for use to reduce and/or treat drug addiction Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,071,093 | Method of Treating Parkinson's Disease with a Diarylmethylpiperazine Compounds Exhibiting Delta Opioid Receptor Agonist Activity Formerly held Term ended Term ended Sep 5, 2026 · High confidence | Term ended | Term ended Sep 5, 2026 | High confidence |
| US 11,246,865 | Opioid for use to reduce and/or treat drug addiction Formerly held Lapsed on the fee record Ended Feb 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 15, 2026 | From the USPTO record |
| US 8,642,599 | Method of Treating Parkinson's Disease with Diarylmethylpiperazine Compounds Exhibiting Delta Receptor Agonist Activity Formerly held Lapsed on the fee record Ended Feb 4, 2026 · High confidence | Lapsed on the fee record | Ended Feb 4, 2026 | High confidence |
| US 9,701,645 | Method of Treating Parkinson's Disease with a Diarylmethylpiperazine Compounds Exhibiting Delta Opioid Receptor Agonist Activity Formerly held Lapsed on the fee record Ended Jul 11, 2025 · High confidence | Lapsed on the fee record | Ended Jul 11, 2025 | High confidence |
| US 6,924,288 | Enantiomerically pure opioid diarylmethylpiperzine and methods of using same Formerly held Term ended Term ended May 1, 2023 · From the USPTO record | Term ended | Term ended May 1, 2023 | From the USPTO record |
| US 8,865,721 | Delta opioid receptor agonist compounds Formerly held Lapsed on the fee record Ended Oct 21, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 21, 2022 | From the USPTO record |
| US 7,189,725 | Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent Formerly held Term ended Term ended Oct 8, 2022 · From the USPTO record | Term ended | Term ended Oct 8, 2022 | From the USPTO record |